Opus is delighted to have advised the shareholders of In2Care, a developer of novel mosquito control products, on its sale to Envu.

In2Care has developed a patented technology called InsecTech®. Applied on netting, the long-lasting static-charged coating can bind all types of biocide powders and transfer lethal doses to mosquitoes. This technology is currently available in a professional mosquito station that thousands of pest control operators are already leveraging in the U.S. to control mosquitoes for homeowner customers.

We are very excited to see the development of the partnership between In2Care and Envu as they work to advance healthy environments by preventing the spread of vector-borne diseases. The transaction is expected to close by the year-end 2024.

Opus previously advised Cinven on their acquisition of Envu, previously Bayer Environmental Sciences, in 2022.

For further information please contact: Dr Chris Carlisle, Daniel Barley

Freddie joined Opus in January 2023 and has gained transactional experience in the Healthcare and Chemicals sectors.

Prior to Opus, Freddie completed his DPhil in Organic Chemistry at the University of Oxford. Whilst at Oxford, he achieved four Full Blues: three in cricket and one in hockey

Ed joined Opus in November 2022 and is aligned with the Chemicals, Healthcare and Consumer and Retail teams.

Prior to joining Opus, Ed worked at KPMG London for 5 years, where he qualified as a chartered accountant. He most recently worked within the Valuations team developing financial models for transactions and providing independent business valuation opinions. He also worked at MARCOL Health – a dedicated Healthcare Private Equity investor – for a year prior to joining KPMG, investing growth capital into owner managed businesses in the UK and Europe.

Ed has a BSc degree in Maths and Physics, and an MSci in Economics, Accounting and Finance from the University of Bristol, and is a member of the ICAEW.

Opus is delighted to have advised Cinven on the $2.6b acquisition of Bayer Environmental Science Professional (BESP), a division of Bayer AG.

Cinven have entered into a definitive agreement to acquire BESP, a global leader in specialty pest management across a range of end-markets. BESP has an extensive product portfolio to manage pests (such as rodents, pest insects and invasive weeds) in a sustainable and responsible manner, including for the vegetation management, range and pasture, forestry and turf and ornamentals markets. Cinven shares management’s ambitious growth agenda and views BESP as a platform investment, with scope to grow the business significantly and broaden its product portfolio through acquisitions and strategic partnerships. The deal also allows Bayer to focus on streamlining its crop science division.

Headquartered in Cary, North Carolina, BES has global operations with c.800 employees c.2000 product registrations, sold in more than a 100 countries and 4 R&D centres worldwide. 

This is another market leading global transaction and milestone in Opus’ Chemicals franchise.

Opus Corporate Finance LLP is delighted to have advised AURELIUS on the sale of Wychem to Ascensus Specialties LLC., a portfolio company of New Mountain Capital and Wind Point Partners.

Wychem is a leading UK-based manufacturer of fine chemicals for pharmaceutical and specialty applications. Using its own process technology, Wychem manufactures starting materials and multi-step intermediates for the synthesis of pharmaceutical APIs and other advanced technology applications. Wychem manufactures over 1,000 products and specialises in the production of aromatic compounds and halogenation.

Ascensus is a leading US-based provider of specialty materials for life sciences and advanced technology markets. It is the global leader in borohydride, borane and specialty alcoholate reagents, CVD/ALD precursors, and high-purity APIs and cGMP materials. This transaction complements Ascensus’ existing capabilities and reinforces the company’s focus on servicing the pharmaceutical sector.

This is an important transaction for Opus, adding to its recent success in the chemicals sector.

For further information please contact: Chris Carlisle, Michael Mizon, Thalia Ilsen Nunn